Business Wire

SES Networks to Provide Connectivity Across Burkina Faso

Share

SES (Euronext Paris:SESG) (LuxX:SESG) announced that it has been selected to lead a project to extend high-speed communications infrastructure throughout Burkina Faso.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170606006791/en/

SES Networks to Provide Connectivity Across Burkina Faso (Photo: Business Wire)

SES Networks to Provide Connectivity Across Burkina Faso (Photo: Business Wire)

SES Networks will be providing the full end-to-end solution, including wireless terrestrial communication and integration with the available optical fibre backbone, to connect 881 sites for e-government, education and health across Burkina Faso. In order to enhance connectivity in the landlocked country, SES Networks will be using high throughput, low latency satellite capacity via its Medium Earth Orbit (MEO) fleet, and will provide managed service and maintenance support from Luxembourg, and through a local presence in Burkina Faso.

The solution is specifically designed for the Support Programme of the Reinforcement of Communication Infrastructures (PARICOM) and supports the Burkina Faso e-governance policy through a Luxembourg development cooperation project. This project is part of the Indicative Cooperation Programme established for the period 2017-2021 between Luxembourg and Burkina Faso. It aims to improve the quality, reliability and accessibility of IT and communication infrastructure throughout the country.

Following the implementation by SES Networks, Burkina Faso will own a high-speed, flexible and reliable telecommunications network for essential government needs, strengthened through satellite technology and additional wireless terrestrial coverage. The terrestrial wireless part of this network will be operated by Burkina Faso’s National Agency for Promotion of Information and Communication Technology (ANPTIC).

“Upon conclusion of the project, Burkina Faso’s administration will enjoy the benefits of a cutting-edge, next-generation network,” said Gerhard Bethscheider, Managing Director at SES Techcom Services, part of the newly-created SES Networks business unit. “The combination of terrestrial and satellite links is the optimal solution in this case, empowering network reliability and increasing IP throughput. We have the necessary capabilities and extensive expertise in delivering such end-to-end solutions, and are ready to replicate this model in other African countries.”

The project follows on SES’s earlier collaboration with Commission Electorale Nationale Independante (CENI), which enabled secure digital transmission of the electoral results of the Burkinabe Presidential Election in 2015.

Follow us on:

Twitter: https://twitter.com/SES_Satellites

LinkedIn: https://www.linkedin.com/company/ses

Facebook: https://www.facebook.com/SES.Satellites

YouTube: http://www.youtube.com/SESVideoChannel

Blog: https://www.ses.com/news/blogs

Media Gallery: https://www.ses.com/media-gallery

SES White papers are available under: https://www.ses.com/news/whitepapers

About SES

SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) television reach in Europe, O3b Networks, a global managed data communications service provider, and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. Further information available at: www.ses.com

Contact information

SES
Markus Payer
Corporate Communications
Tel. +352 710 725 500
Markus.Payer@ses.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New data show first-line triplet regimen of pembrolizumab, Herzuma® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer29.5.2020 02:01:00 EESTPress release

Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma ® (biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC). The PANTHERA trial (a phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2-positive gastric cancer), sponsored by Celltrion Inc. and MSD, is investigating the potential of a first-line immunotherapy/chemotherapy combination with biosimilar trastuzumab. This is in light of a growing body of evidence that the immune system contributes to the therapeutic effects of monoclonal antibodies such as biosimilar trastuzumab in treating solid tumours.1 A total of 43 patients were treated with a median follow up of 18 months. Patients were treated with pembrolizumab 200mg via IV infusion D1, biosimilar trastuzumab 6mg/kg (after 8mg/kg load) D1, capecitabine 1000mg/m2 bid D1-D1

European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP64729.5.2020 02:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announces that on May 28, the European Commission (the “EC”) has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights (“SHP647”), a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc (“Shire”). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access (“PTA”) study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn’s & Colitis Foundation (“Foundation”). Takeda announced on November 20, 2018, that the EC approved its proposed acquisition of Shire (the “Acquisition”). The EC’s appr

Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent28.5.2020 19:02:00 EESTPress release

Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease. Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000. “We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charit

JRJ Group Announces Sale of ETX Capital to Guru Capital28.5.2020 16:30:00 EESTPress release

JRJ Group, a leading international private equity investment firm focused on the financial services sector and growth situations, is pleased to announce that it has agreed to terms for the sale of ETX Capital, one of the fastest growing international providers of multi-asset CFDs and spread betting products, to a fund associated with Guru Capital, a Switzerland-based private equity firm with specific experience in the CFD space. Terms of the transaction were not disclosed. Roger Nagioff, Founding Partner of JRJ Group, said, “During JRJ’s ownership, we have invested in bolt-on acquisitions and enhanced the technology of the firm. We are delighted with the strength and resilience of the platform we have built, alongside the management team and employees, and we wish the enterprise every success in its next stage of growth.” “We are grateful of JRJ Group’s support, and we look forward to growing the business with the Guru Capital team, who have substantial experience in the CFD sector,” s

eLichens Launches eStore for US and EU Markets28.5.2020 16:00:00 EESTPress release

French start-up eLichens has launched its online store last week. eLos, for eLichens Outdoor Station, can now be purchased online by US and EU customers. Japan and other areas will soon join the list. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005117/en/ (Photo: Business Wire) eLos is a wireless, solar-powered air quality station. eLos provides citizens, communities and organizations the most accurate and complete real-time data about air quality, wherever they need it. Visit the store and learn more about eLos : https://www.elichens.com/store/elos View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005117/en/ Contact information Marc Attia, press@elichens.com

SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate28.5.2020 15:24:00 EESTPress release

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced in vitro data demonstrating that SAB-185, its COVID-19 therapeutic candidate, has highly-potent neutralizing antibodies to SARS-CoV-2 that are four times higher than the most potent human convalescent plasma serum sample evaluated. The company also announced that they initiated manufacturing of SAB-185 on May 25 to support the next phase of clinical development for its potential COVID-19 therapeutic, still on track to begin human trials in early summer. “These data indicate this human polyclonal antibody therapeutic has potent neutralizing activity against live SARS-CoV-2. The neutralizing titers of SAB-185 are significantly higher than those of the most potent plasma of recovered COVID-19 patients we’ve been able to source,” said William B. Klimstra, PhD Associate Professor of Microbio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom